Silvant Capital Management LLC Acquires 2,655 Shares of Insulet Corporation $PODD

Silvant Capital Management LLC raised its holdings in Insulet Corporation (NASDAQ:PODD) by 20.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,404 shares of the medical instruments supplier’s stock after acquiring an additional 2,655 shares during the period. Silvant Capital Management LLC’s holdings in Insulet were worth $4,756,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Sage Mountain Advisors LLC raised its stake in Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 33 shares in the last quarter. Glenmede Investment Management LP grew its stake in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC increased its holdings in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares during the last quarter. WINTON GROUP Ltd raised its position in shares of Insulet by 0.9% during the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 37 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd lifted its holdings in shares of Insulet by 28.7% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 39 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PODD shares. UBS Group restated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Sanford C. Bernstein decreased their price objective on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. JPMorgan Chase & Co. dropped their target price on Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research report on Thursday, February 19th. Finally, Leerink Partners reduced their price target on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $354.24.

Insulet Price Performance

PODD opened at $230.49 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The stock’s 50 day simple moving average is $256.02 and its 200 day simple moving average is $295.24. The firm has a market cap of $16.23 billion, a price-to-earnings ratio of 65.85, a PEG ratio of 1.34 and a beta of 1.42. Insulet Corporation has a 1 year low of $216.49 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.15 earnings per share. As a group, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Michael R. Minogue purchased 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.39% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.